Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain

NCT03213457 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03213457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
July 7, 2017
Completion date
December 6, 2023
Enrollment
681 (actual)
Sites
197

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis